MRD articles & resources on Made-in-China.com

Molecular Diagnostics Firm Inostics Has Received The License From Clia

Jun 4, 2013

Inostics, a molecular diagnostics firm providing blood-based mutation testing, has received the Clinical Laboratory Improvement Amendments (CLIA) license for its clinical laboratory in Baltimore. The receipt of the license would mark a ...

Tags: Clia Certification, Medicine

Clonosight Mrd Test Is Introduced by Sequenta

Feb 19, 2013

Sequenta has introduced a sequencing-based test for minimal residual disease (MRD) for leukemia and lymphoma. The ClonoSIGHT test utilizes the company's proprietary LymphoSIGHT technology, which works by sequencing DNA signatures that are ...

Tags: Sequenta, sequencing-based test, minimal residual disease

Sequenta LymphoSIGHT Method Will Be Used by Eastern in E1411 Phase II Trial

Dec 18, 2012

Eastern Cooperative Oncology Group, now a part of the ECOG-ACRIN Cancer Research Group, has entered into an agreement to use Sequenta's new LymphoSIGHT sequencing method in its randomized E1411 phase II trial. LymphoSIGHT is designed for ...

Tags: Eastern Cooperative Oncology Group, LymphoSIGHT

SWOG Has Chosen Sequenta's LymphoSIGHT Platform for The Measurement

Dec 4, 2012

SWOG (formerly the Southwest Oncology Group) has chosen Sequenta's LymphoSIGHT platform for the measurement of minimal residual disease (MRD) in 180-patient mantle cell lymphoma clinical trial. The patients in the SWOG S1106 mantle cell ...

Tags: SWOG, Sequenta's LymphoSIGHT platform, minimal residual disease, MRD

MRD

Molecular Diagnostics Firm Inostics Has Received The License From Clia

Clonosight Mrd Test Is Introduced by Sequenta

Sequenta LymphoSIGHT Method Will Be Used by Eastern in E1411 Phase II Trial

SWOG Has Chosen Sequenta's LymphoSIGHT Platform for The Measurement

Related Products